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Abstract
Background: Analyses of Expressed Sequence Tags (ESTs) databases suggest that most human
genes have multiple alternative splice variants. The alternative splicing of pre-mRNA is tightly
regulated during development and in different tissue types. Changes in splicing patterns have been
described in disease states. Recently, we used whole-transcriptome shotgun pryrosequencing to
characterize 4 malignant pleural mesothelioma (MPM) tumors, 1 lung adenocarcinoma and 1
normal lung. We hypothesized that alternative splicing profiles might be detected in the sequencing
data for the expressed genes in these samples.
Methods: We developed a software pipeline to map the transcriptome read sequences of the 4
MPM samples and 1 normal lung sample onto known exon junction sequences in the
comprehensive AceView database of expressed sequences and to count how many reads map to
each junction. 13,274,187 transcriptome reads generated by the Roche/454 sequencing platform
for 5 samples were compared with 151,486 exon junctions from the AceView database. The exon
junction expression index (EJEI) was calculated for each exon junction in each sample to measure
the differential expression of alternative splicing events. Top ten exon junctions with the largest
EJEI difference between the 4 mesothelioma and the normal lung sample were then examined for
differential expression using Quantitative Real Time PCR (qRT-PCR) in the 5 sequenced samples.
Two of the differentially expressed exon junctions (ACTG2.aAug05 and CDK4.aAug05) were
further examined with qRT-PCR in additional 18 MPM and 18 normal lung specimens.
Results: We found 70,953 exon junctions covered by at least one sequence read in at least one
of the 5 samples. All 10 identified most differentially expressed exon junctions were validated as
present by RT-PCR, and 8 were differentially expressed exactly as predicted by the sequence
analysis. The differential expression of the AceView exon junctions for the ACTG2 and CDK4
genes were also observed to be statistically significant in an additional 18 MPM and 18 normal lung
samples examined using qRT-PCR. The differential expression of these two junctions was shown
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to successfully classify these mesothelioma and normal lung specimens with high sensitivity (89%
and 78%, respectively).
Conclusion:  Whole-transcriptome shotgun sequencing, combined with a downstream
bioinformatics pipeline, provides powerful tools for the identification of differentially expressed
exon junctions resulting from alternative splice variants. The alternatively spliced genes discovered
in the study could serve as useful diagnostic markers as well as potential therapeutic targets for
MPM.
Background
Alternative splicing of pre-mRNA is a post-transcriptional
process that occurs in approximately 70% or more of all
human genes presumably to increase the diversity of the
transcriptome and proteome [1]. This process is tightly
regulated during development and is different among dif-
ferent tissue types. Inherited and acquired changes in pre-
mRNA splicing patterns have been reported in many
human malignancies, including colorectal cancer [2],
ovarian cancer [3], breast cancer [4], and lung cancer
[5,6]. In some cases, specific alternative splicing variants
have been proposed as potential clinical markers for can-
cer diagnosis [7,8] and prognosis [8] as well as function in
the role of therapeutic targets [9].
To-date, several groups have reported their efforts to iden-
tify novel alternatively spliced genes by analyzing the pub-
lic available Expressed Sequence Tag (EST) databases [10-
12]. Microarray based methods have also been developed
to characterize cancer related alternative splicing events
using exon arrays and exon junction arrays [13]. Recently,
we used whole-transcriptome shotgun pyrosequencing
[14] to characterize the transcriptome profiles of individ-
ual MPM patient samples and controls obtained at surgery
[15]. Approximately 1.6 Gb of sequence data was
obtained from ~16 million sequencing reads of ~105 bp
average length. We hypothesized that differentially
expressed alternative splicing events might be observed in
these sequencing datasets.
In the present study, we demonstrate i) that cancer linked
alternative splicing profiles can be identified in second
generation transcriptome sequencing data in silico by
mapping all sequence reads onto previously observed
exon junction sequences, ii) that this approach can be
used to identify expressed exons that are not present in the
RefSeq mRNA database at NCBI, and iii) that specific exon
junctions can be used to discriminate among MPM and
normal samples.
Methods
Sequencing data and patient samples
Whole-transcriptome pyrosequencing [14] was previously
described for 4 MPM tumors, 1 lung cancer and 1 normal
lung using the Roche/454 sequencing system [15]. For
this investigation, we used subset of those samples includ-
ing all 4 MPM samples and one normal sample. Briefly,
for each sample, >260 Mb of transcriptome sequence were
obtained by shotgun, clonal pyrosequencing using Roch/
454 technology. This subset consisted of 13,274,187 total
sequencing reads of 105 bp average length. Overall, 98%
of the reads matched to human RNA, DNA, and mito-
chondrial DNA sequences. In each sample, ~15,000
known RefSeq genes were detected by at least one read.
Additional 36 human discarded tissue specimens (n = 18
MPM, n = 18 normal lung) were acquired from our insti-
tution's Tumor Bank and used in compliance with a
research protocol approved by the Institutional Review
Board at Brigham and Women's Hospital.
AceView transcriptome database
AceView is a public database provided by the National
Library of Medicine which provides a comprehensive
annotation of transcripts and genes based on data from
GeneBank, dbEST and RefSeq. This database was reported
to offer a richer view of human transcriptome with 3 to 5
times more high-quality transcript forms than the pub-
licly available databases (e.g., UCSC known genes, RefSeq
or Ensemble) [16]. The AceView database of human tran-
scribed sequences ('Aug05') and genome coordinate file
('hg17, May 2004') in GFF format (General Feature For-
mat, is a format for describing genes and other features
associated with DNA, RNA and Protein sequences) were
obtained from the AceView website [16] and used to
define the sequences and locations for 151,486 unique
exon junctions.
Annotation of AceView exon junctions and creation of 
virtual probes
A customized Active State Perl script was used to index all
possible exon junctions for each AceView transcript
according to the genomic coordinates of the 3' end of the
donor exon and the 5' end of accepter exon that define the
exon junction. In Aceview database, there are often multi-
ple transcripts for each gene, so exon junctions with the
same (or similar) chromosomal coordinates from differ-
ent transcript of the same gene will have same mRNA
sequence around it. In order to generate non-redundant
virtual probe sequences, we eliminated the redundantBMC Medical Genetics 2009, 10:149 http://www.biomedcentral.com/1471-2350/10/149
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exon junctions with smaller than 5 bp differences. For
each exon junction, a 200 bp transcript segment including
100 bp on each side of the exon junction point was
extracted from the longest AceView transcript which con-
tains the exon junction to create a virtual probe sequence
for the exon junction. The name of the longest AceView
transcript ID containing the junction and exon junction
location in the transcript was used as a unique identifier
for the exon junction and for the associated virtual probe
sequence. For example, the exon junction
'ACTG2.aAug05.574' defines a junction that occurs in the
ACTG2 gene in Aceview transcript 'a' in the 'Aug05' data-
base at nucleotide position 574. These probes were also
linked to relevant NCBI accession numbers, whenever
possible.
Mapping of 454 transcriptome reads onto virtual probes
The alignment code was run on the Partners Healthcare
System High Performance Computing Cluster based on
the Microsoft HPC Server 2008 Operating system. NCBI
blastall was used to map all the 454 transcriptome reads
onto the virtual probe sequences with the following
parameters: blastall -p blastn -a 2 -F "m D" -e 1e-10 -m 8.
A customized Perl script was used to query the blast results
to quantify the number of reads mapping to each virtual
probe and cover the junction point with at least 5 bp on
both side, at least 35 bp of continuous alignment, and at
least 90% identity to the virtual probe sequence. Figure 1
illustrates the theoretical alignment of the ~100 bp long
transcriptome reads with the different exon junctions
spanned by virtual probes.
Filtering of mapped exon junctions and generation of an 
exon junction expression index (EJEI)
To filter out the low-expressed exon junctions across all
samples, we required that each unique exon junction map
to at least 5 sequencing reads in all patients combined. To
filter out the low-expressed genes in any single sample, we
also required that at least 4 sequencing reads map to any
exon junction in a given gene in each sample. Because
there are similar total numbers of reads among the 5 dis-
covery samples [15], additional normalization to the total
read count in each sample was unnecessary.
To correct for systematic differences in gene expression
levels between the different samples, an exon junction
expression index (EJEI) was calculated for each unique
exon junction in each sample. The EJEI is the ratio of
number of reads that cover a specific exon junction
divided by the total number of the reads that map to any
of the exon junctions of the gene. This is similar to the
Splicing Index reported in ArrayAssist software [17] for
analyzing the exon level data on the Affymetrix Exon
arrays, however, here we are counting the relative fre-
quency of the exon junctions themselves.
To make the EJEIs comparable among different exon junc-
tions of different genes, they were further normalized by
the sum of the EJEI in all patients for the same exon junc-
tion. To identify highly expressed exon junctions in MPM
relative to normal lung, we generated a ranked list of EJEIs
by calculating the differences between the minimum nor-
malized EJEI in the 4 MPM samples and the normalized
EJEI for the same exon junction in the normal lung sam-
ple. To identify highly expressed exon junctions in normal
lung relative to MPM, we similarly generated a ranked list
of EJEIs by calculating the difference between the normal-
ized EJEI in the normal lung sample and the maximum
normalized EJEI for the same exon junction in the four
MPM samples.
Quantitative Real Time RT-PCR
Total RNA (2 μg) was reverse-transcribed into cDNA using
Taq-Man Reverse Transcription reagents (Applied Biosys-
tems, Foster City, CA) and quantified using all recom-
mended controls. Primers (synthesized by Invitrogen Life
Technologies) were used at a final concentration of 800
nM in the reaction mixture and are shown in additional
file 1. Primer sequences were blasted onto NCBI human
Identification of alternatively spliced transcripts using second  generation sequencing data Figure 1
Identification of alternatively spliced transcripts 
using second generation sequencing data. The 454 
sequencing reads that span exon junctions provide informa-
tion about alternatively spliced variants in the human tran-
scriptome. For example, two typical alternatively spliced 
variants ('a' and 'b') of a single gene are shown in the top half 
of the figure. The lower half of the figure shows how differ-
ent 454 reads may align to cDNA sequences generated from 
the mRNA providing evidence of alternatively splicing events.BMC Medical Genetics 2009, 10:149 http://www.biomedcentral.com/1471-2350/10/149
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Refseq RNA database to confirm that the primers will not
amplify other genes. PCR amplification and SYBR-Green-
based detection of cDNA was performed using a Strata-
gene MX3000P machine and default thermal cycling
parameters. No-template (i.e., negative) controls that con-
tained water instead of template were run in multiple
wells on every reaction plate. An automatically calculated
melting point disassociation curve generated after every
assay was examined to ensure the presence of a single PCR
species and the lack of primer-dimer formation in each
well. (The detail method is in Additional file 2).
Statistical analysis
Average expression levels of exon junctions were com-
pared between MPM and normal samples using a two-
tailed student's t-test. Classification accuracy was assessed
using a 2 × 2 contingency table and Fisher's exact test. All
comparisons were considered statistically significant if P <
0.05. All comparisons were conducted using S-PLUS soft-
ware [18]. Post-hoc power analysis was conducted using
G*Power [19].
Results
In total, we indexed 151,486 unique AceView exon junc-
tions to create one virtual probe per unique exon junction.
Mapping of the 13,274,187 transcriptome reads against
these 151,486 virtual probes revealed 70,953 exon junc-
tions that were covered by at least one sequence read in at
least one of the 5 samples using our criteria. The distribu-
tion of these 70,953 exon junctions was summarized in
Additional file 3.
We used ranked normalized EJEI values to identify the
most differentially expressed exon junctions between the
four MPM samples and the one normal lung sample. All
the exon junctions with EJEI difference bigger than 0.1
were listed examined (see Additional file 4). We identified
76 highly expressed unique exon junctions in MPM and
32 unique highly expressed exon junctions in the normal
lung sample (see Additional file 5). We chose to examine
in the 5 discovery samples a total of 10 exon junctions: the
top 3 ranked exon junctions expressed at relatively higher
levels in normal lung and the top 7 ranked exon junctions
expressed at relatively higher levels in the MPM samples
using real time quantitative RTPCR (see table 1 and addi-
tional file 6 for the 10 candidate exon junctions). We arbi-
trarily weighted our list towards exon junctions over-
expressed in MPM tumor because we found more highly
expressed exon junctions in MPM (76) than in normal
lung (32) and sought to increase our chances of identify-
ing potentially diagnostic alternatively spliced transcripts.
We were able to validate that all predicted exon junctions
were actually observed in the transcriptome when the
samples were independently analyzed with qRT-PCR. Six
of the 10 candidate exon junctions analyzed with qRT-
PCR have a level of expression in the normal lung sample
within the range of expression of the 4 MPM tumors. As
far as the differential expression was concerned, we
required that the individual expression level of each exon
junction in at least 2 of the 4 MPM tumors (and the aver-
age for all 4 MPM tumors) be in the predicted direction
relative to the level in the normal lung sample. We were
able to validate the differential expression of 8 of the 10
exon junctions. Differential expression of exon junctions
'EMP2.shed3.aAug05' (over-expressed in normal) and
'DNAJB11.aAug05' (over-expressed in tumor) observed
using 454 sequence data could not be confirmed by qRT-
PCR. In both cases, expression of the exon junction was
detected at similarly high levels in all samples using qRT-
PCR (see table 1 and additional file 6 for detail compari-
son between qRT-PCR results and transcriptome sequenc-
ing results).
Among the 8 validated differentially expressed exon junc-
tions, we selected 'ACTG2.aAug05' and 'CDK4.aAug05'
for further evaluation in a set of 18 additional MPM sam-
ples and 18 normal lung samples using qRT-PCR. These
two exon junctions were selected because they were asso-
ciated with the greatest magnitude of differential expres-
sion in the predicted direction for each of the 5 discovery
samples using both 454 read counts and qRT-PCR. We
found that the average expression levels of both
'ACTG2.aAug05' and 'CDK4.aAug05' were statistically sig-
nificantly different in the predicted direction between
normal and tumor samples (P = 0.00054 and P = 0.00039,
respectively, Figure 2A and 2B). 'ACTG2.aAug05' was
associated with a greater range of expression levels across
individual samples (~100-fold difference) than
'CDK4.aAug05' (~3-fold difference).
Using the median value of relative exon junction expres-
sion levels in all 36 samples as a cut-off, we found that
'ACTG2.aAug05' expression correctly classified 89% (16/
18 tumor, 16/18 normal) of the samples (P = 5.2 × 10-6,
Figure 2C), whereas 'CDK4.aAug05' correctly classified
78% (14/18 tumor, 14/18 normal) of the samples (P = 2.2
× 10-3, Figure 2D). All 36 samples were correctly classified
by at least one exon junction. Using G*Power, post-hoc
power analysis show sufficient sample size with Power (1-
β err prob) = 1.000 for ACTG.aAug05 and Power (1-β err
prob) = 0.997 for CDK.aAug05.
Discussion
There have been previous reports of alternatively spliced
cancer-associated genes that could serve as diagnostic and
prognostic markers as well as guide to potential therapeu-
tic targets [10-12]. These studies used a variety of tools
including analysis of publicly available databases and dis-
covery using microarrays, both of which utilize high-B
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Table 1: Normalized EJEI and corresponding RT-PCR results for the top ten differentially expressed exon junctions*
Normalized EJEI RT-PCR EJEI result
Normal/
Tumor
Gene Typical AceView 
sequence
Exon 
junction 
location in 
typical 
AceView 
sequence
Meso 1 Meso 2 Meso 3 Meso 4 normal 
lung
Normalized 
Meso and 
Normal EJEI 
difference
Meso 1 Meso 2 Meso 3 Meso 4 normal 
lung
normal EMP2 EMP2.shed3.aAug05 1003 0.000 0.000 0.000 0.000 1.000 1.000 0.079 0.065 0.069 0.071 0.069
normal CYFIP1 CYFIP1.fAug05 49 0.000 0.000 0.000 0.000 1.000 1.000 0.034 0.056 0.043 0.044 0.052
normal ACTG2 ACTG2.aAug05 574 0.062 0.000 0.000 0.000 0.938 0.876 0.026 0.054 0.029 0.079 0.209
tumor C1QA and 
C1QG
C1QAandC1QG.aAu
g05
1449 0.221 0.264 0.229 0.286 0.000 0.221 0.139 0.115 0.220 0.190 0.148
tumor MRPL51 MRPL51.bAug05 542 0.228 0.301 0.215 0.256 0.000 0.215 0.678 0.908 0.710 0.664 0.693
tumor TXNRD1 TXNRD1.aAug05 1333 0.198 0.220 0.363 0.219 0.000 0.198 0.570 0.507 0.520 0.546 0.461
tumor CDK4 CDK4.aAug05 1246 0.267 0.223 0.196 0.314 0.000 0.196 2.014 1.495 1.454 1.395 1.248
tumor hfl-B5 hfl-B5.aAug05 1123 0.225 0.226 0.252 0.256 0.040 0.185 0.897 0.772 0.835 0.654 0.686
tumor COL3A1 COL3A1.aAug05 1680 0.184 0.363 0.195 0.258 0.000 0.184 0.228 0.336 0.230 0.183 0.168
tumor DNAJB11 DNAJB11.aAug05 1612 0.265 0.281 0.271 0.183 0.000 0.183 1.094 1.165 1.316 1.280 1.286
*Note: this is the brief version of additional file 6BMC Medical Genetics 2009, 10:149 http://www.biomedcentral.com/1471-2350/10/149
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throughput methods to characterize cancer related alter-
native gene splicing [13,20]. More recently, a high
throughput RT-PCR method has been used to measure the
differential expression of 3,327 alternative splicing events
in 600 cancer-related genes for ovarian and breast cancer
[3,21]. The present study provides one of the first attempts
to show how whole transcriptome sequencing using mas-
sive parallel sequencing technology can be used to simul-
taneously profile as many as 151,486 alternative splicing
events in cancer patient samples for all the human genes
cataloged in the comprehensive AceView database of tran-
scribed sequences. In our previously study [15], we used
the Roche/454 next-generation sequencing system for
whole transcriptome pyrosequencing of cDNA samples
for 4 MPM tumors, 1 lung adenocarcinoma and 1 normal
lung. We generated between 2.5 and 2.9 million shotgun
sequencing reads for each sample of average length ~105
bp and focused on the identification of novel Single
Nucleotide Polymophisms (SNPs) in the expressed
sequences. Herein, we hypothesized that these same tran-
scriptome reads could be used to detect alternatively
spliced genes in the patient samples by mapping all the
read sequences onto known exon junction sequences as
virtual probes. Using a subset of the same dataset [15], we
have developed a software pipeline to quantify the expres-
sion levels of exon junctions by counting the number of
reads that match to each exon junction to identify cancer
related alternative splicing pattern.
In this study, we have identified several genes expressing
alternatively spliced transcripts at different levels in the
tumors and in the matching normal lungs. Many of these
genes have been previously implicated in cancer. ACTG2
contains one 5' un-translated exon and 8 coding exons
Differential expression of specific exon junctions in MPM and normal lung samples Figure 2
Differential expression of specific exon junctions in MPM and normal lung samples. Average expression levels of 
exon junctions in ACTG2 (A) and CDK4 (B) differ statistically significantly between MPM and normal lung samples. Individual 
expression levels of exon junctions in ACTG2 (C) and CDK4 (D) can be used to classify MPM and normal tissue samples using 
the median value as a cut-off. Error bars, SEM. Arrows indicate misclassified samples.BMC Medical Genetics 2009, 10:149 http://www.biomedcentral.com/1471-2350/10/149
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spanning 27 kb [22]. This gene has 7 known splicing var-
iants shown in AceView website [16], but none of them
has been directly related to cancer. An expression microar-
ray analysis performed on a derivate breast cancer cell line
resistant to cisplatin showed that ACTG2 expression
increases in the chemotherapy resistant cell line compared
to the normal indicating that it may be associated with cis-
platin resistance [23]. In another study, ACTG2 expres-
sion was identified as cadmium-responsive [24]. The
authors concluded that repressed expression of ACTG2
following cadmium exposure may contribute to the cell
cycle arrest. CDK4 is a well-known for its role in cancer
[25]. It is a cyclin-dependent kinase-4 involved in the cell
cycle and can both start and stop the cell cycle in response
to proliferative or anti-proliferative signals. It has 13
known splice variants according to AceView website [16].
Several reports have already linked CDK4 expression to
mesothelioma [26,27]. However, this was the first study
showing that different CDK4 splice variants have differen-
tial expression levels in MPM and matching normal lung.
The differentially expressed splice variants for ACGT2 and
CDK4 were specifically chosen for further examination
using qRT-PCR in additional 18 MPM and matched nor-
mal lung samples. This analysis suggested that the differ-
entially expressed splice variants may provide reliable
markers for disease and be used to classify the samples
with high sensitivity and specificity.
Several of the other genes that appeared to exhibit differ-
entially expressed splice variants in the present study have
also been implicated in cancer and would be worthy of
further study. CYFIP1 has been shown to be a novel tyro-
sine kinase substrate in a breast cancer model [28]. Inter-
estingly, the differentially expressed transcript
(CYFIP1.fAug05) is not included in NCBI Refseq
sequence database. It has been suggested that COL3A1
could be a potential diagnostic marker for large B-cell
lymphoma (DLBCL) as is shows statistically significant
different expression between DLBCL and follicular lym-
phoma [29]. In addition, COL3A1 expression has been
related to resistance to platinum drugs in ovarian cancer
[30]. TXNRD1 is a key enzyme in the regulation of the
intracellular redox environment [31]. Transcription of
TXNRD1 involves alternative splicing, leading to a
number of transcripts. In particular, expression of the
TXNRD1_v3 transcript has been found in several cancer
cell lines [32]. Recently, its locus has been associated with
advanced colorectal adenoma by epidemiologic and ani-
mal studies [33].
In this pilot study, we were not able to find statistical dif-
ference between differentially expressed exon junctions
because of the small sample size (only 4 MPM and 1 nor-
mal lung sample), neither we were able to compare the
results among different platforms. In addition, not all
exon junctions predicted to be differentially expressed
proved to be so to the same extent when examined with
the qRT-PCR. This is likely due the limited number of
specimens examined. Furthermore, the signal to noise
ratio may have been over-amplified as not to miss any
potential differentially expressed candidates. After all, the
EJEI was designed to magnify the differential expression
and is not in the same order of magnitude as the actual
expression of the exon junctions. Other potential limita-
tions may be due to sequencing artifacts, insufficient
sequencing depth, SNPs near the EJ and incomplete data-
base for possible exon junctions. These limitations may be
avoided using other next-generation sequencing plat-
forms, such as Helicos True Single Molecule Sequencing
without amplification, Illumina or SOLiD [34], or by
increasing the sequencing depth. Nevertheless, at least 2
of the top 10 exon junctions prioritized for analysis
remained differentially expressed in most tested speci-
mens supporting the utility of this approach.
The present study provides an example of a possible appli-
cation of advanced sequencing technologies in cancer
research. The current sequencing technologies are now
capable of generating millions of shotgun transcriptome
reads in a matter of days. For example, the latest Roche/
454 GS FLX Titanium system generates over 1,000,000
reads of average length 400 bp in one 10-hour sequencing
run providing orders of magnitude improvement in speed
and cost over conventional Sanger-based sequencing. One
of the great virtues of the shogun transcriptome sequenc-
ing process is that there is no need to impose any bias for
known genes, exons, or splice-junctions as required for
example with exon microarrays. As these technologies
continue to improve their throughput and read lengths
and lower their costs, they promise to revolutionize gene
expression analysis by simultaneously providing informa-
tion about expression levels, transcript variants, and SNPs.
The greater challenge for the successful application these
technologies for our understanding of health and disease
will be the analysis and interpretation of the data. Here we
have introduced a data analysis pipeline to map
13,274,187 transcriptome reads from patient cDNA sam-
ples onto 151,486 known splice junctions cataloged in
the comprehensive AveView database of transcribed
sequences. However, in short order we can expect that the
competing next generation sequencing technologies will
be generating several orders of magnitude more transcrip-
tome and genomic sequencing data for a wide variety of
human diseases and cancer. Further advances in the bio-
informatics analysis of this flood of data are clearly
required, for example, to map sequencing reads directly to
human genome to identify novel transcribed sequencesBMC Medical Genetics 2009, 10:149 http://www.biomedcentral.com/1471-2350/10/149
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and genes, alternative exons and splicing events, and pos-
sible gene fusions in patient samples
Conclusion
We demonstrated that whole-transcriptome shotgun
sequencing and downstream bioinformatics pipeline can
be powerful high-throughput tools for the identification
of differentially expressed exon junctions resulting from
alternative splicing variants. The alternative transcripts
discovered in the study could be useful as diagnostic
markers as well as potential therapeutic targets for MPM.
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